Cloperastine or cloperastin, in the forms of cloperastine hydrochloride and cloperastine fendizoate, is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, Brazil and in some European countries. It was first introduced clinically in Japan and subsequently characterized for its pharmacology, safety and formulation optimization; chemically it is a substituted piperidine derivative available as salts to modify solubility and pharmacokinetics. Pharmacologically cloperastine combines central antitussive activity with H1 histamine receptor antagonism and demonstrable peripheral sensory nerve desensitization and mild local anesthetic effects, yielding efficacy against both reflex and irritation driven cough. Typical pharmaceutical presentations are oral syrups and tablets formulated from the hydrochloride or fendizoate salts; the compound undergoes hepatic metabolism, shows moderate oral bioavailability and is assayed and controlled in quality programs using HPLC, LC-MS and related analytical techniques.
Cloperastine impurity and related compound control focuses on synthetic impurities, hydrolysis and N-dealkylation products, and residual solvents; common related substances observed in stability and forced-degradation studies include dealkylated, dehalogenated and ester hydrolysis species. Typical specification limits used in development and quality control are individual related substances not greater than 0.2 percent w/w, any single specified impurity not greater than 0.3 percent w/w when justified, total impurities not greater than 1.0 percent w/w, and potential genotoxic impurities controlled to 0.05 percent w/w or to the appropriate threshold of toxicological concern. Analytical approaches to quantify and identify these impurities employ gradient HPLC with UV detection and confirmatory LC-MS, with GC used for residual solvents and stability indicating methods used for forced degradation under acidic, basic, oxidative, thermal and photolytic conditions.
Cloperastine is used as a cough suppressant for symptomatic relief of dry and irritation driven cough; because it combines antitussive and antihistamine properties it is used when cough has a component of airway irritation or allergic contribution and is supplied as oral formulations based on the hydrochloride or fendizoate salts.
Yes sedation is a known adverse effect because of H1 histamine receptor antagonism; the degree of somnolence varies between individuals and formulations and should be considered when operating machinery or driving.
Copastin is a trade name for a cloperastine-containing product and is used as an antitussive cough suppressant; product labeling and local regulatory approvals determine recommended dosing, contraindications and safety information.
Cloperastine fendizoate acts via the same core mechanisms as cloperastine hydrochloride; molecular activity includes central suppression of the cough reflex, peripheral sensory nerve desensitization and H1 receptor antagonism, with enyancement of absorption or altered pharmacokinetics provided by the fendizoate salt form. The precise molecular targets in the central cough center are not fully defined, so activity is described by pharmacodynamic outcomes observed in preclinical and clinical studies.
